ping an-乐鱼官方网站在线登陆入口

font size:
乐鱼官方网站在线登陆入口-乐鱼官方网站在线登录入口
online message
contact information
one of telephone, mobile phone number, e-mail is required
contact
tel
mobile phone
email
qq
wechat account
message
other additions
verification code
development history
2021
  • c&o pharmaceutical technology (holdings) limited was merged into ping an-shionogi co., ltd.
2021
2020
  • a joint venture of ping an-shionogi co., ltd. was established by shionogi (hong kong) co., ltd. and ping an life insurance company of china, ltd. in shanghai in november, 2020.
  • march，ping an insurance (group) company of china, ltd. took a stake in shionogi & co. ltd. becoming its seventh largest shareholder.
2020
2019
  • shionogi became the controlling shareholder with shareholding of 100% held in c&o.
2019
2015
  • construction for c&o’s new production base was completed and put into use.
2015
2014
  • c&o launched the first “injection of rabeprazole sodium - aobo ping®” in china, which is the independently developed product.
2014
2011
  • shionogi became the controlling shareholder of c&o.
  • c&o was appointed as the exclusive distributor of flumarin® in china by shionogi.
2011
2010
  • sumitomo became the strategic shareholder with shareholding of 29% held in c&o.
2010
2008
  • acquired 100% shareholding in nanjing xinaokang
  • established the joint venture with xenobiotic laboratories, inc., a principal contract research service provider in the united states
2008
2007
  • c&o was appointed as the distributor of the new generation cephalosporin antibiotics, ”meiact” for the whole of china by shantou meiji pharmaceuticals co., ltd.
  • c&o was appointed as the exclusive distributor of “europharm cough syrup for children - pholcotussin” in china by europharm laboratories co. ltd.
2007
2006
  • acquired 100% shareholding in shenzhen liancheng
  • acquired 69.98% shareholding in shanghai sun-sail
2006
2001
  • acquired 100% shareholding in nanjing chang ao
  • nanjing chang ao established the research and development center to conduct the relevant activities for c&o.
  • nanjing chang ao obtained the gmp certification by the sfda.
  • pharmaceutical laboratories limited.
2001
2000
  • expanded the freeze-dried powder workshop, ointment and cream workshops
2000
1999
  • expanded the pharmaceutical center, including the tablets and capsules workshop, and raw materials workshop
1999
1997
  • nanjing chang ao was established and engaged in the manufacture and sales of own branded products.
1997
1995
  • c&o was established and engaged in the manufacture and sales of own branded products and distribution of third parties’ products
1995
about us
about us development history company honor
business scope
market sales technology development manufacture center
products
antibiotics digestive system medication cardiovascular and cerebrovascular medication bone and muscle medication dermatological medication respiratory system medication medical device
news release
company news notice
contact us
  • official wechat account official wechat account
  • mobile pagemobile page
  • service tel0755-2552 7000
  • business tel0755-2552 7386
linkssite mapprivacy policy
乐鱼官方网站在线登录入口 copyright @ 2022 c&o pharmaceutical technology (holdings) limited. all rights reserved.
网站地图